96.36
Schlusskurs vom Vortag:
$96.73
Offen:
$96.74
24-Stunden-Volumen:
1.12M
Relative Volume:
1.19
Marktkapitalisierung:
$5.51B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-32.55
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-1.93%
1M Leistung:
-3.78%
6M Leistung:
-39.82%
1J Leistung:
-21.51%
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GKOS
Glaukos Corporation
|
96.36 | 5.61B | 360.35M | -149.57M | -81.27M | -2.96 |
![]()
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
2024-12-06 | Eingeleitet | UBS | Buy |
2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
2023-11-28 | Eingeleitet | Truist | Buy |
2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-12-22 | Eingeleitet | Mizuho | Neutral |
2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
2022-10-14 | Fortgesetzt | Stephens | Overweight |
2022-10-04 | Eingeleitet | Needham | Buy |
2022-07-12 | Hochstufung | Stifel | Hold → Buy |
2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
2020-12-09 | Eingeleitet | Oppenheimer | Perform |
2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-06-15 | Eingeleitet | Jefferies | Hold |
2020-03-05 | Eingeleitet | Citigroup | Sell |
2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
2019-03-08 | Eingeleitet | BTIG Research | Neutral |
2018-08-30 | Eingeleitet | Berenberg | Hold |
2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
2018-08-03 | Bestätigt | Stifel | Hold |
2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-04-13 | Herabstufung | Stifel | Buy → Hold |
2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
2017-01-06 | Hochstufung | Stifel | Hold → Buy |
2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Why We're Not Concerned About Glaukos Corporation's (NYSE:GKOS) Share Price - 富途牛牛
Glaukos Corporation Stock Analysis and ForecastExceptional market positioning - jammulinksnews.com
What analysts say about Glaukos Corporation stockRapid wealth creation - jammulinksnews.com
What drives Glaukos Corporation stock priceFree Daily Trading Room Entry - Autocar Professional
Is Glaukos Corporation a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
What analysts say about Glaukos Corporation stock outlookFree Insider Trading Tips - beatles.ru
Midday Stock Roundup: loanDepot Shoots Up 16% - Orange County Business Journal
September 19th Options Now Available For Glaukos (GKOS) - Nasdaq
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $117 - 富途牛牛
(GKOS) Investment Report - news.stocktradersdaily.com
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - simplywall.st
BTIG Increases Glaukos (GKOS) Price Target Ahead of Q2 Results | - GuruFocus
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 - BioSpace
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks - Yahoo Finance
Glaukos to Release Second Quarter 2025 Financial Results after M - GuruFocus
Press Release: Glaukos to Release Second Quarter 2025 Financial Results After Market Close on July 30 - 富途牛牛
Glaukos Prepares for New Product Launches - Orange County Business Journal
Glaukos Corporation(NYSE: GKOS) added to Russell 2000 Defensive Index - MarketScreener
Glaukos gains EU certification for iStent infinite and other MIGS devices - Yahoo Finance
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies - BioSpace
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies | GKOS Stock News - GuruFocus
Trend Tracker for (GKOS) - news.stocktradersdaily.com
Glaukos Receives EU Regulatory Certification for Devices and Technologies to Treat Glaucoma - 富途牛牛
Glaukos Corporation: Delivering Consistent Growth (NYSE:GKOS) - Seeking Alpha
Glaukos Trades Higher Than Medical Peers NYSE Composite - Kalkine Media
What Makes Glaukos (GKOS) a New Buy Stock - Yahoo Finance
Trading (GKOS) With Integrated Risk Controls - news.stocktradersdaily.com
Piper Sandler names Abbott, Edwards, Glaukos as top medtech catalyst picks - Investing.com Canada
Glaukos Corp (GKOS) Shares Up 6.05% on Jun 11 - GuruFocus
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect? - sharewise
Here’s Why Glaukos (GKOS) Shares Traded Lower in Q1 - Insider Monkey
Stifel maintains buy rating on Glaukos stock, $115 target unchanged By Investing.com - Investing.com India
Glaukos at Jefferies Conference: Eyeing Interventional Success By Investing.com - Investing.com South Africa
Glaukos at Jefferies Conference: Eyeing Interventional Success - Investing.com
Stifel maintains buy rating on Glaukos stock, $115 target unchanged - Investing.com
Glaukos at William Blair Conference: Eyeing Innovative Growth By Investing.com - Investing.com South Africa
glaukos corp reports annual meeting voting results By Investing.com - Investing.com South Africa
glaukos corp reports annual meeting voting results - Investing.com
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):